SCHEMBL19781280

SCHEMBL19781280

CC(C)Oc1ccc(-n2cnc3cnc(-c4ccc(C(C)(C)O)cc4)nc32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.39
NT5E P21589 1/20 0.37
MAPT P10636 2/20 0.36
PTGES O14684 1/20 0.36
MCHR1 Q99705 1/20 0.35
CYP11B2 P19099 1/20 0.35
MAPK6 Q16659 1/20 0.35
WNT1 P04628 1/20 0.35
CLK2 P49760 1/20 0.35
CLK3 P49761 1/20 0.35
DYRK1A Q13627 1/20 0.35
CYP3A4 P08684 2/20 0.34
CYP3A5 P20815 2/20 0.34
HPGD P15428 3/20 0.34
SYK P43405 2/20 0.34
RPS6KA3 P51812 1/20 0.34
PTPN5 P54829 1/20 0.33
ATM Q13315 1/20 0.33
KMT2A Q03164 1/20 0.33
PTK2B Q14289 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781608 0.90 FGFR1 (0.46) FGFR1NT5EMAPTMCHR1CYP11B2
SCHEMBL19781531 0.84 DYRK1A (0.45) FGFR1MAPTPTGESMCHR1CYP11B2
SCHEMBL19781604 0.79 KCNH2 (0.48) FGFR1MAPTPTGESMCHR1HPGD
SCHEMBL19781574 0.78 FGFR1 (0.49) FGFR1MAPTPTGESMCHR1HPGD
SCHEMBL21449952 0.77 GABRP (0.43) FGFR1NT5EMCHR1DYRK1A
SCHEMBL19781259 0.75 FGFR1 (0.47) FGFR1MAPTMCHR1CYP11B2MAPK6
SCHEMBL22071823 0.74 FGFR1 (0.48) FGFR1MAPTPTGESMCHR1HPGD
SCHEMBL19781576 0.73 DYRK1A (0.50) FGFR1MAPTMCHR1CYP11B2DYRK1A
Lhf-535 SCHEMBL15201523 0.72 FGFR1 (0.53) FGFR1MAPTHPGD
Lhf-535 SCHEMBL30055835 0.72 FGFR1 (0.53) FGFR1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S FGFR1 3928/4885NT5E 2850/4885MAPT 4633/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S FGFR1 3928/4885NT5E 2850/4885MAPT 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.